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Cell cycle progression is regulated by cyclin-dependent kinases (CDKs), whose activation requires
the binding of regulatory subunits named cyclins. RINGO/Speedy A is a mammalian protein that
has no amino acid sequence homology with cyclins but can activate CDKs. Here we show that
RINGO/Speedy A is a highly unstable protein whose expression and phosphorylation are periodically
regulated during the cell cycle. RINGO/Speedy A is degraded by the proteasome and the process
involves the ubiquitin ligase SCFSkp2. Overexpression of a stabilized RINGO/Speedy A form results
in the accumulation of high levels of RINGO/Speedy A at late stages of mitosis, which interfere with
cytokinesis and chromosome decondensation. Our data show that tight regulation of RINGO/Speedy
A is important for the somatic cell cycle.
Structured summary:
MINT-7226413:RINGO A (uniprotkb:Q5MJ70) physically interacts (MI:0914) with Ubiquitin (uni-
protkb:P62988) by anti bait coimmunoprecipitation (MI:0006)MINT-7226431, MINT-7226448:RINGO A
(uniprotkb:Q5MJ70) physically interacts (MI:0914) with Skp2 (uniprotkb:Q13309) by anti tag coimmuno-
precipitation (MI:0007)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The mammalian cell division cycle is governed by the periodical
activation of cyclin-dependent kinases (CDKs), whose activity is
modulated by the binding of regulatory subunits named cyclins.
Two mechanisms that contribute to the periodical accumulation
of cyclins during cell cycle progression are transcriptional activation
and protein destruction. Cyclin degradation is mediated by the
ubiquitin-proteasome system (UPS) and involves the covalent
attachment of a chain of ubiquitin molecules to the cyclin by the
sequential action of three enzymes, referred to as E1, E2 and the
ubiquitin ligase E3 [1]. Twomajor classes of ubiquitin ligases medi-
ate ubiquitination of cyclins: the SCF (Skp1-Cul1-F-box protein) and
the APC/C (Anaphase Promoting Complex/Cyclosome) complexes
[2–4]. The proteolysis of cyclins by the UPS is a keymechanism that
ensures accurate levels of CDK activity during the cell cycle. Consis-
tently, overexpression of non-degradable cyclin mutants impairs
cell cycle progression [5,6]. Some cyclins have also been reported
to be phosphorylated in a cell cycle-dependent manner [7].
RINGO/Speedy proteins can bind to and activate CDKs in spite of
having no amino acid sequence similarity to cyclins [8,9]. The ﬁrst
member of this family was identiﬁed as a potent inducer of themei-
otic maturation in Xenopus oocytes [10,11]. A mammalian homo-chemical Societies. Published by Elogue was subsequently identiﬁed and named Spy1; this protein
was proposed to regulate cell cycle progression via CDK2 activation
and p27Kip1 phosphorylation [12]. More recently, ﬁve different
mammalian members of this protein family have been described
with Spy1 corresponding to RINGO/Speedy A [13]. Intriguingly,
the distant family member RINGO/Speedy E has been proposed to
negatively regulate cell cycle progression [14]. To understand the
contribution of RINGO/Speedy proteins to the periodical activation
of CDKs, it is important to know their regulation during the cell cy-
cle. In this regard, Xenopus RINGO/Speedy accumulates transiently
during the meiotic cell cycle of oocytes owing to a tight control
by the UPS [15]. Here, we report the regulation of RINGO/Speedy
A (RINGO A for simplicity) during themammalianmitotic cell cycle.2. Materials and methods
2.1. Expression constructs
Details on DNA cloning and mutagenesis are provided as Sup-
plementary data.
2.2. Cell culture and manipulation
The protocols used for cell culture and transfection, time-lapse
microscopy, immunoﬂuorescence, ﬂow cytometry analysis and
qRT-PCR are indicated in Supplementary data.lsevier B.V. All rights reserved.
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dazole (100 ng/ml) for 16 h followed by mechanical shake-off.
The G1 population was obtained releasing mitotic cells into fresh
medium for 4 or 8 h, corresponding to G1a or G1b phases, respec-
tively. In experiments with only one G1 time point, this corre-
sponds to 8 h after release. For G1/S synchronization, cells were
incubated in medium containing Thymidine (2.5 mM) for 16 h, re-
leased into fresh medium for 10 h and then incubated again with
2.5 mM Thymidine for another 12 h. These cells were released into
fresh medium for 5 or 9 h to obtain S and G2 phase populations,
respectively.
2.3. Protein analysis
Cell pellets were resuspended in cold IP buffer containing
50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA,
0.1 mM Na Vanadate, 1 mM PMSF, 2 lM microcystin, 2.5 mM ben-
zamidine and 10 lg/ml each of aprotinin, leupeptin and pepstatin.Fig. 1. RINGO A regulation during the cell cycle. (A) Relative amounts of RINGO A, cyclin
cells. Transcript levels were determined by qRT-PCR and were normalized using asyn
Supplementary Fig. S1. (B) U2OS cells were transfected with the indicated RINGO A con
protein accumulation in U2OS cells synchronized in different cell cycle stages. (D) Cel
nocodazole to induce RINGO A expression and mitotic arrest, respectively. Cell lysates
phosphatase and the other not, and were analysed by immunoblotting. (E) U2OS cells ex
Ser242-249 all changed to Ala) were synchronized in different cell cycle stages and total
transfected U2OS cells. Arrowheads indicate phosphorylated RINGO A forms.Lysates were centrifuged at maximal speed in an Eppendorf centri-
fuge for 15 min at 4 C and the supernatants were used for immu-
noprecipitation, immunoblotting, kinase assays, ubiquitination
assays or alkaline phosphatase treatments as indicated in Supple-
mentary data.
3. Results
3.1. RINGO A regulation during the cell cycle
Expression of cyclins is tightly regulated during the cell cycle by
several mechanisms, including transcriptional activation. Previous
work, using RT-PCR, has reported that RINGO A mRNA was exclu-
sively expressed at the G1/S transition in synchronized 293T cells
[16]. In contrast, we detected the RINGO A mRNA in all stages of
the cell cycle in two human cell lines, U2OS and HeLa, using quan-
titative RT-PCR (qRT-PCR) (Supplementary Fig. S1). Differences in
the techniques used for cellular synchronization and transcriptA2, cyclin E1 and control mRNA levels in different stages of the cell cycle in U2OS
chronous population (AS) levels as a reference. Cell cycle proﬁles are shown in
structs and 24 h later total lysates were analysed by immunoblotting. (C) RINGO A
ls expressing inducible 6Myc-RINGO A were treated with both tetracycline and
were split in two aliquots that were processed equally but one received alkaline
pressing RINGO A wild-type (WT) or the phosphorylation mutant (with Thr10 and
lysates were analysed by immunoblotting. Control lysates were prepared from non-
2774 A. Dinarina et al. / FEBS Letters 583 (2009) 2772–2778analysis might account for the discrepancies with previous reports
[16]. The relative RINGO A transcript levels oscillated during cell
cycle progression so that they were higher in M phase and lower
in G1 phase, resulting in an expression pattern nearly identical to
that for cyclin A2 (Fig. 1A and Supplementary Fig. S1). Cyclin E
mRNA levels were lower in the M and G1 phases and higher during
S phase entry, in agreement with previous reports [17].Fig. 2. GFP-RINGO A expression impairs cell cycle progression. (A and C) U2OS cells we
indicated in the upper right corner. Scale bar, 10 mm. (B) Images of GFP-RINGO A-transfe
magniﬁcation objectives, as indicated. GFP-RINGO A positive cells connected via a cytop
GFP-RINGO A. Phosphorylation of Ser10-histone H3 (P-H3), a mitotic marker, was examin
were co-transfected with GFP or GFP-RINGO A, either WT or with Asp135, Glu136
immunoprecipitated with GFP antibody and analysed by immunoblotting with FLAG an
staining of H1 is shown as a loading control. (F) U2OS cells were transfected with GF
connected with a cytoplasmic bridge were scored and represented as percentage of tranCyclins accumulate periodically during cell cycle progression
at both mRNA and protein levels [18]. To follow the expression
pattern of the endogenous RINGO A protein during the cell cy-
cle, we generated sensitive antibodies that could detect as little
as 1 ng of recombinant RINGO A protein. Nevertheless, we have
not been able to detect the endogenous protein in cell lines
that express RINGO A mRNA (not shown), indicating thatre transfected with GFP-RINGO A and were analysed by video microscopy. Time is
cted cells were acquired in transmission and ﬂuorescent channels using 10 or 40
lasmic bridge are indicated by white arrows. (D) U2OS cells were transfected with
ed by immunoﬂuorescence 24 h after transfection. Scale bars, 10 mm. (E) 293T cells
and Glu137 changed to Ala (DEE mutant), and FLAG-CDK2. Total lysates were
tibody to detect CDK2, as well as by kinase activity towards Histone H1. Coomassie
P or GFP-RINGO A-WT and -DEE and 24 h later individual rounded cells and cells
sfected cells.
Fig. 3. Degradation of RINGO A by the UPS. (A) U2OS cells stably expressing Myc-
RINGO A were incubated either with DMSO for 5 h or with MG-132 (25 lM) for the
indicated times and the lysates were analysed by immunoblotting. Control lysates
were prepared from non-transfected U2OS cells. (B) U2OS cells expressing Myc-
RINGO A were pre-incubated with DMSO or MG-132 (25 lM) for 2 h prior to
cycloheximide addition (CHX, 30 lg/ml). Cells were collected at the indicated times
after CHX addition and the expression of RINGO A was determined by immuno-
blotting. Quantiﬁcation of the blots is shown in the lower panel. (C) U2OS cells were
transfected with HA-ubiquitin (HA-Ub) or 6Myc-RINGO A and incubated with
MG-132. Cell lysates were immunoprecipitated with RINGO A antibody and then
blotted with HA or RINGO A antibodies, as indicated.
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noticed that even the overexpressed RINGO A protein was dif-
ﬁcult to detect, which is consistent with previous reports show-
ing poor expression of transfected RINGO A, unless the N-
terminal 60 amino acids were deleted [9]. We found that N-ter-
minal tagging improved the accumulation of transfected RINGO
A, with a good correlation between the size of the N-terminal
tag and RINGO A expression levels, so that a fusion to GFP
was better expressed than to 6Myc and this better than a fu-
sion to 1Myc (Fig. 1B). To follow the accumulation of RINGO
A protein during the cell cycle, we generated a mammalian cell
line that constitutively expressed Myc-RINGO A. These cells
were synchronized at different stages of the cell cycle and
the levels of RINGO A protein were analysed by immunoblot-
ting (Fig. 1C). We found that RINGO A accumulated periodically,
being higher in G1 phase, although small levels were detectable
in all cell cycle stages. As expected, endogenous A and B-type
cyclins also accumulated periodically in our experiments. Thus,
RINGO A is both transcriptionally and post-transcriptionally reg-
ulated during the cell cycle. Indeed, the apparent discrepancy
between the peaks of RINGO A mRNA and protein levels during
cell cycle progression resembles human cyclin A regulation [19],
whose mRNA levels peak in mitosis when the protein is already
absent due to proteasomal degradation (see also Fig. 1A and C).
This suggests a possible high turnover rate for RINGO A in
mitosis.
3.2. RINGO A protein is phosphorylated in mitosis
RINGO A usually appeared as a smear in immunoblottings of
mitotic cell extracts (Fig. 1C–E, arrowheads). Since these changes
in electrophoretic mobility are usually associated with protein
modiﬁcations, mostly phosphorylation, we tested the possibility
that the shifted RINGO A bands represented phosphorylated forms.
To be able to analyse the low amounts of RINGO A protein present
in mitotic cell extracts, we generated a U2OS-derived cell line
expressing Tetracycline-inducible 6Myc-RINGO A (Supplemen-
tary Fig. S2). By immunoblotting, we detected several 6Myc-
RINGO A bands in extracts of mitotic cells (Fig. 1D, arrowheads).
Incubation of the extracts with alkaline phosphatase converted
the slower migrating RINGO A forms to a faster migrating form,
indicating that this protein was phosphorylated in mitosis, proba-
bly at multiple sites. To identify phosphorylated residues in RINGO
A, we generated a collection of mutants with potential phosphory-
lation residues changed to Ala (Supplementary Fig. S3). We found
that mutation of an N-terminal Thr-Pro site together with muta-
tion of a stretch of eight Ser located in the C-terminus abolished
the mitotic shift (Fig. 1E and Supplementary Fig. S3, mutant C).
Next, we generated a cell line that constitutively expressed the
phosphorylation-deﬁcient RINGO A mutant and analysed its accu-
mulation during the cell cycle. We found that the cell cycle accu-
mulation proﬁles of wild-type (WT) RINGO A and the non-
phosphorylatable mutant were very similar, except in mitosis
where the mutant did not display the characteristic band shift
and appeared as a single fast-migrating band (Fig. 1E, arrowheads).
These results indicate that RINGO A is hyper-phosphorylated in
mitosis. However, this phosphorylation does not appear to have a
major effect on RINGO A protein accumulation during the cell
cycle.
3.3. Overexpression of a stabilized RINGO A form impairs cell cycle
progression
A fusion with GFP was the best expressed form of RINGO A that
we could obtain (Fig. 1B), indicating that this fusion protein was
more resistant to the degradation mechanisms that conferred poorexpression to other RINGO A constructs. Since degradation-resis-
tant mutants of cyclins are known to impair cell cycle progression
[5,6], we investigated the effect of GFP-RINGO A on the cell cycle.
By using live-cell video microscopy, we found that about half
(54 ± 12%) of the cells expressing GFP-RINGO A progressed nor-
mally through the cell cycle and showed only transient RINGO A
accumulation. Typically, the protein appeared shortly after mitosis
and was then degraded (Fig. 2A; Supplementary movies 1 and 2), in
agreement with the results from our synchronization experiments
(Fig. 1C and E). However, the other half of the GFP-RINGO A-
expressing cells (46 ± 12%) displayed cell cycle abnormalities. In
particular, these cells had a rounded morphology and were often
connected in pairs via what we referred to as the cytoplasmic
bridge (Fig. 2B). The cytoplasmic bridge frequently contained a
structure similar to the midbody, suggesting a cytokinesis defect
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played constitutive RINGO A expression after mitosis, which usu-
ally resulted in cell rounding (Fig. 2C; Supplementary movies 3
and 4). Frequently, two connected cells fused back in a single cell
(Fig. 2C; Supplementary movie 4), resembling the ‘‘reversal of
mitosis exit” process observed upon forced stabilization of cyclin
B in mitosis [20]. In addition, these cells showed abnormal chroma-
tin condensation and morphology (Fig. 2D). We have not observed
a similar phenotype by overexpressing other RINGO A constructs
that are expressed at lower levels, such as 6Myc-tagged forms.
We therefore believe that this phenotype is a direct consequence
of the presence of high levels of GFP-RINGO A protein.
Given that RINGO A can activate CDKs, primarily CDK2, it is
possible that unscheduled and/or increased CDK activity result-Fig. 4. RINGO A degradation is mediated by Skp2. (A) U2OS cells expressing Myc-RIN
transfection were incubated with Nocodazole. Asynchronous and mitotic cell population
panels. (B) U2OS cells were transfected with HA-Skp2 and Myc-RINGO A, as indicated. T
antibodies and then were analysed by immunoblotting. (C) U2OS cells were co-transfecte
the indicated siRNAs. Cell lysates were immunoprecipitated with RINGO A antibody an
strong accumulation of 6Myc-RINGO A in contrast with Myc-RINGO A.ing from RINGO A accumulation at late stages of mitosis may
interfere with cell cycle progression. To test this possibility we
mutated residues 135–137 of RINGO A to Ala and conﬁrmed that
this mutant (RINGO A-DEE) was unable to bind to and activate
CDK2 (Fig. 2E), as expected from the mutation of equivalent res-
idues in Xenopus RINGO and mammalian RINGO E [8]. Interest-
ingly, GFP-RINGO A-DEE induced neither the appearance of
cells with rounded morphology nor cells connected via the cyto-
plasmic bridge (Fig. 2F), even when expressed at the same level
as GFP-RINGO A wild-type (Supplementary Fig. S4). This data
suggests that high levels of GFP-RINGO A impair cell cycle pro-
gression by a mechanism that involves binding to endogenous
CDKs.GO A were transfected with control, Cdc20, Cdh1 or Skp2 siRNAs and 48 h after
s were analysed by immunoblotting. Flow cytometry analysis are shown in the right
otal lysates were immunoprecipitated with HA (upper panel) or Myc (lower panel)
d with HA-ubiquitin or 6Myc-RINGO A and 24 h later were transfected again with
d then immunoblotted with HA antibody. Note that Skp2 depletion did not cause
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Proteolysis mediated by the UPS is a key mechanism controlling
cyclin levels during the cell cycle [18]. To examine whether RINGO
A levels were regulated by the UPS, we treated RINGO A-expressing
U2OS cells with the proteasome inhibitor MG-132. This resulted in
rapid RINGO A accumulation (Fig. 3A), indicating a fast turn-over of
RINGO A in proliferating cells. By treating cells with the protein
synthesis inhibitor cycloheximide, we estimated that the half-life
of RINGO A was less than 15 min (Fig. 3B). As expected, MG-132
signiﬁcantly increased the half-life of RINGO A in the presence of
cycloheximide.
Interestingly, GFP tagged RINGO A protein also showed an in-
creased half-life (Supplementary Fig. S5). To examine whether
RINGO A was ubiquitinated, U2OS cells were co-transfected with
RINGO A and HA-tagged ubiquitin. We detected high molecular
weight HA-immunoreactive forms in the RINGO A immunoprecip-
itates, which were conﬁrmed to correspond to the ubiquitinated
RINGO A by re-probing with a RINGO A antibody (Fig. 3C).
3.5. SCF-Skp2 mediates RINGO A degradation
Since SCF and APC/C complexes are two important ubiquitin li-
gases controlling the timely proteolysis of cell cycle regulators, we
investigated their implication in UPS-mediated RINGO A degrada-
tion. We used siRNA against the APC/C activators Cdc20 and
Cdh1 as well as against Skp2, the F-box protein of SCF. Downregu-
lation of Skp2, but not of Cdc20 or Cdh1, resulted in RINGO A accu-
mulation in both asynchronous and mitotic cells suggesting that
SCF-Skp2 complex could be involved in RINGO A degradation
(Fig. 4A, left). As a control, treatment with Skp2 siRNA also induced
accumulation of p27Kip1, a well-known Skp2 substrate [21]. We
conﬁrmed that RINGO A accumulation was not a consequence of
changes in cell cycle distribution induced by Skp2 siRNA (Fig. 4A,
right). Interestingly, overexpressed RINGO A co-immunoprecipi-
tated with Skp2 (Fig. 4B) and Skp2 downregulation impaired
RINGO A ubiquitination in cells (Fig. 4C). We also observed that
the expression of Skp2 inversely correlated with the accumulation
of RINGO A during the cell cycle (Fig. 1C), supporting the idea that
Skp2 mediates RINGO A ubiquitination and degradation.4. Discussion
Our data indicate that the similarity between RINGO/Speedy
proteins and cyclins goes beyond CDK binding and activation. Like
cyclins, RINGO A is a very unstable protein that is periodically ex-
pressed during the cell cycle and is degraded by the UPS. We found
that the SCFSkp2 ubiquitin ligase is a good candidate to regulate
RINGO A ubiquitination and degradation. It has been recently pro-
posed that NEDD4, a HECT-type ubiquitin ligase, might target
RINGO A for degradation [22]. Although we have not tested this
possibility, it is well documented that Skp2 substrates are usually
targeted by additional ubiquitin ligases [21].
Overexpression of a stabilized form of RINGO A fused to GFP im-
pairs cell cycle progression. In particular, a high percentage of the
cells expressing GFP-RINGO A at late stages of mitosis round up
and stop cycling. These cells often show a phenotype similar to
what has been reported for cells that express high levels of non-
degradable cyclin B [23] or cells that undergo the process called
‘‘reversal of mitotic exit” [20] in which cyclin B accumulation in-
duces premature CDK1 activation and prevents mitotic exit. Simi-
larly, mutation of the RINGO A core, which is essential for CDK
binding, abolishes the negative effects of GFP-RINGO A expression
on cell cycle progression suggesting that these are likely due to
unscheduled activation of CDK/RINGO A complexes. The tight con-trol of RINGO A protein levels by UPS-mediated degradation could
be important to ensure the low levels of CDK activity required for
some cell cycle transitions, such as mitotic exit. RINGO A binds to
and activates preferentially CDK2, but it can also bind to CDK1
when both proteins are overexpressed [8]. Although CDK2 has
been mainly implicated in S-phase, it also coordinates mitotic
events [24]. Indeed, downregulation of RINGO A results in delayed
progression both at G1/S and G2/M transitions (unpublished data).
It remains to be elucidated whether binding to CDK2 accounts for
the phenotype induced by RINGO A overexpression and, in this
case, which substrates could be targeted by the CDK2/RINGO A
complex. Given the central role of Skp2 in promoting tumorigene-
sis, which cannot always be explained by p27Kip1 downregulation
[21], it would be also interesting to elucidate the biological rele-
vance of RINGO A regulation by Skp2, determining precisely the
timing and the events that lead to its degradation.
Future studies should investigate how RINGO A interplays with
cyclins to tightly regulate CDK activity during cell cycle progres-
sion and how timely expression and degradation of these proteins
coordinate cell cycle events by selectively targeting CDKs to spe-
ciﬁc substrates.
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